LCM Capital Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
VCM
VPM
LCM Capital Management's BMY Position: Q1 2026 in Review
LCM Capital Management increased its Bristol-Myers Squibb (BMY) stake by 0.45% in Q1 2026, buying an estimated $2.33K and bringing the position to 8,885 shares worth $539K. The position accounts for 0.27% of the portfolio, ranked #49.
LCM Capital Management first reported a position in BMY in Q4 2020 and has held it in 22 quarters since. The position peaked at $755K in Q2 2022. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- LCM Capital Management held 8,885 shares of Bristol-Myers Squibb worth $539K as of Q1 2026.
- LCM Capital Management bought 40 Bristol-Myers Squibb shares in Q1 2026, an estimated $2.33K.
- Bristol-Myers Squibb made up 0.27% of LCM Capital Management's portfolio in Q1 2026, its #49 holding.
- LCM Capital Management first reported a position in Bristol-Myers Squibb in Q4 2020 and has held it in 22 quarters since.
- LCM Capital Management's Bristol-Myers Squibb position peaked at $755K in Q2 2022.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on LCM Capital Management's 13F filing for Q1 2026, filed 21 Apr 2026.